#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
preLekára.sk / Journals / Internal Medicine / 2019 - 11

The myths and facts about arterial hypertension: do we really know everything about arterial hypertension?

Česká verzia

Authors: Anna Vachulová
Authors place of work: Národný ústav srdcových a cievnych chorôb a. s., Klinika kardiológie a angiológie, oddelenie arytmií a kardiostimulácie, Bratislava, Slovenská republika
Published in the journal: Vnitř Lék 2019; 65(11): 728-733
Category: Actualities

Summary

Arterial hypertension is one of the most commonly underestimated diseases. At the same time various myths are frequently associated with this illness. Likewise, the overload of available clinical data causes misconceptions, which then lead to the misinterpretation of real and also doubtful issues. Unfortunately, these misconceptions result in insufficient blood pressure control. Let’s sort through some common myths in our article, so you can make health decisions in the management of hypertension based on the facts.

Keywords:

amlodipine – arterial hypertension – fixed dosed combination treatment – indapamide – perindopril arginine

Zdroje
  1. Poulter NR, Prabhakaran D, Caulfield M. Hypertension. Lancet 2015; 386(9995): 801–812. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(14)61468–9>.
  2. Burnier M. Antihypertensive Combination Treatment. State of the Art. Curr Hypertens Rep 2015; 17(7): 51. Dostupné z DOI: <http://dx.doi.org/10.1007/s11906–015–0562–0>.
  3. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31(7): 1281–357. Dostupné z DOI: <http://dx.doi.org/10.1097/01.hjh.0000431740.32696.cc>.
  4. Williams B, Mancia G, Spieringet W et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J 2018; 39(33): 3021–3104. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehy339>.
  5. Ettehad D, Emdin CA, Kiran et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta- analysis. Lancet 2016; 387(10022): 957–967. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(15)01225–8>.
  6. Lewington S, Clarke R, Qizilbash N et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360(9349):1903–1913. Dostupné z DOI: <http://dx.doi.org/10.1016/s0140–6736(02)11911–8>.
  7. Wenxin Xu, Saveli I Goldberg, Maria Shubina. Optimal systolic blood pressure target, time to intensification, and time to follow-up in treatment of hypertension: population based retrospective cohort study. BMJ 2015; 350: h158. Dostupné z DOI: <http://dx.doi.org/10.1136/bmj.h158>.
  8. Mancia G, Rea F, Corrao G et al. Two-Drug Combinations as First-Step Antihypertensive Treatment. Circ Res 2019; 124(7): 1113–1123. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCRESAHA.118.313294>.
  9. Redon J, Erdine S, Böhm M et al. Physician attitudes to blood pressure control: findings from the Supporting Hypertension Awareness and Research Europe-wide survey. J Hypertension 2011; 29; 1633–1640. Dostupné z DOI: <http://dx.doi.org/10.1097/HJH.0b013e328348c934>.
  10. Vrijens B, Vincze G, Kristanto P et al. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 2008; 336(7653): 1114–1117. Dostupné z DOI: <http://dx.doi.org/10.1136/bmj.39553.670231.25>.
  11. Wald DS, Law M, Morris JK et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009; 122(3): 290–300. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjmed.2008.09.038>.
  12. Tóth K. [PIANIST Investigators]. Antihypertensive efficacy of triple combination perindopril/indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus AmlodipiNe in high rISk hyperTensive patients). Am J Cardiovasc Drugs 2014; 14(2): 137–145. Dostupné z DOI: <http://dx.doi.org/10.1007/s40256–014–0067–2>. Erratum in Am J Cardiovasc Drugs 2014; 14(3): 239.
  13. Marshall T. How many antihypertensives do patients need to achieve a target blood pressure? J Hum Hypertens 2005; 19(4): 317–319. Dostupné z DOI: <http://dx.doi.org/10.1038/sj.jhh.1001823>.
  14. Abegaz TM, Shehab A, Gebreyohannes EA et al. Nonadherence to antihypertensive drugs A systematic review and meta-analysis. Medicine (Baltimore) 2017; 96(4): e5641. Dostupné z DOI: <http://dx.doi.org/10.1097/MD.0000000000005641>.
  15. Ceral J, Habrdova V, Vorisek V et al. Difficult-to-control arterial hypertension or uncooperative patients? The assessment of serum antihypertensive drug levels to differentiate non-responsiveness from non-adherence to recommended therapy. Hyperten Res 2011; 34: 87–90. Dostupné z DOI: <http://dx.doi.org/10.1038/hr.2010.183>.
  16. Tomaszewski M, White C, Patel P et al. High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis. Heart 2014; 100(11): 855–861. Dostupné z DOI: <http://dx.doi.org/10.1136/heartjnl-2013–305063>.
  17. Florczak E, Tokarczyk B, Warchoł-Celińska E. Assessment of adherence to treatment in patients with resistant hypertension using toxicological serum analysis. A subgroup evaluation of the RESIST-POL study. Pol Arch Med Wewn 2015; 125(1–2): 65–72.
  18. Jung O, Gechter, J; Wunder C et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens 2013; 31(4): 766–774. Dostupné z DOI: <http://dx.doi.org/10.1097/HJH.0b013e32835e2286>.
  19. Xie L, Frech-Tamas F, Marrett E et al. A medication adherence and persistence comparison of hypertensive patients treated with single-, double- and triple-pill combination therapy. Curr Med Res Opin 2014; 30(12): 2415–2422. Dostupné z DOI: <http://dx.doi.org/10.1185/03007995.2014.964853>.
  20. Corrao G, Parodi A, Nicotra F et al. Better compliance to antihypertensive medications reduces cardiovascular risk. J Hypertens 2011; 29(3): 610–618. Dostupné z DOI: <http://dx.doi.org/10.1097/HJH.0b013e328342ca97>.
  21. Roy L, White-Guay B, Dorais M et al. Adherence to antihypertensive agents improves risk reduction of end-stage renal disease. Kidney Int 2013; 84(3): 570–577. Dostupné z DOI: <http://dx.doi.org/10.1038/ki.2013.103>.
  22. Mazza A, Lenti S, Schiavon L et al. Fixed-Dose Triple Combination of Antihypertensive Drugs Improves Blood Pressure Control: From Clinical Trials to Clinical Practice. Adv Ther 2017; 34(4): 975–985. Dostupné z DOI: <http://dx.doi.org/10.1007/s12325–017–0511–1>.
  23. Verma S, Strauss M. Angiotensin receptor blockers and myocardial infarction. BMJ 2004; 329(7477): 1248–1249. Dostupné z DOI: <http://dx.doi.org/10.1136/bmj.329.7477.1248>.
  24. Van Vark LC, Bertrand M, Akkerhuis KM et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J 2012; 33(16): 2088–2097. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehs075>.
  25. Strauss MH, Hall AS. The Divergent Cardiovascular Effects of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Myocardial Infarction and Death. Prog Cardiovasc Dis 2016; 58(5): 473–482. Dostupné z DOI: <http://dx.doi.org10.1016/j.pcad.2015.11.004>.
  26. Strauss MH, Hall AS. Angiotensin Receptor Blockers Do Not Reduce Risk of Myocardial Infarction, Cardiovascular Death, or Total Mortality: Further Evidence for the ARB-MI Paradox. Circulation 2017; 135(22): 2088–2090. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.117.026112>.
  27. Savarese G, Costanzo P, Cleland JG et al. A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure. J Am Coll Cardiol 2013; 61(2): 131–142. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2012.10.011>.
  28. Knuuti J, Wijns W, Saraste A et al. [ESC Scientific Document Group]. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2019; pii: ehz425. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehz425>.
  29. Roush GC, Ernst ME, Kostis JB et al. Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects. Hypertension 2015; 65(5): 1041–1046. Dostupné z DOI: <http://dx.doi.org/10.1161/HYPERTENSIONAHA.114.05021>.
  30. Karpov YA. [FORTISSIMO physicians]. Full-dose Perindopril/Indapamide in the Treatment of Difficult-to-Control Hypertension: The FORTISSIMO Study. Clin Drug Investig 2017; 37(2): 207–217. Dostupné z DOI: <http://dx.doi.org/10.1007/s40261–016–0479–7>. Erratum in Erratum to: Full-dose Perindopril/Indapamide in the Treatment of Difficult-to-Control Hypertension: The FORTISSIMO Study. [Clin Drug Investig 2017].
  31. Parati G, Stergiou G, O‘Brien E et al. [European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability]. European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens 2014; 32(7):1359–1366. Dostupné z DOI: <http://doi: 10.1097/HJH.0000000000000221>.
  32. James PA1, Oparil S2, Carter BL et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311(5): 507–520. Dostupné z DOI: <http://doi: 10.1001/jama.2013.284427>.
  33. Go AS, Bauman MA, Coleman King SM et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. Hypertension 2014; 63(4): 878–885. Dostupné z DOI: <http://doi: 10.1161/HYP.0000000000000003>.
  34. Gabb GM, Mangoni AA, Anderson CS et al. Guideline for the diagnosis and management of hypertension in adults – 2016. Med J Aust 2016; 205(2): 85–89. Dostupné z DOI: <http://doi: 10.5694/mja16.00526>.
  35. Schwartzbard AZ, Newman JD, Howard S. Weintraub HS et alThe 2017 high blood pressure clinical practice guideline: The old and the new. Clin Cardiol 2018; 41(3): 279–281. Dostupné z DOI: <http://doi: 10.1002/clc.22905>.
Štítky
Diabetology Endocrinology Internal medicine
Článek Functional gastrointestinal disorders and pain
Článek May warfarin prevent cancer?
Článek Immunodeficiency in the differential diagnosis of interstitial lung diseases
Článek Why rapid achievement of goal blood pressure is important in the treatment of arterial hypertension
Článek Interferon-alpha in the treatment of myeloproliferative diseases
Článek Pancytopenia, panhypopituitarism and liver cirrhosis: analysis of a difficult clinical case
Článek Vitamin D deficiency and its health effects
Článek Sekundární prevence ischemické choroby srdeční a chorob periferních tepen kombinací antiagregační a antikoagulační léčby Odborné stanovisko České kardiologické společnosti, České internistické společnosti ČLS J.E. Purkyně a České angiologické společnosti ČLS J.E. Purkyně k výsledkům studie COMPASS
Článek Odešel profesor Ivo Dvořák
Článek Primář Jiří Spáčil oslavil 80. narozeniny
Článek Profesor Jan Petrášek slaví devadesáté narozeniny
Článek Spinal epidural abscess – a rare complication of Crohn´s disease: case report
Článok vyšiel v časopise

Internal Medicine

Číslo 11
2019 Číslo 11
Najčítanejšie tento týždeň
Najčítanejšie v tomto čísle
Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa

#ADS_BOTTOM_SCRIPTS#